DSC Advisors’s Travere Therapeutics TVTX Stock Holding History

DSC Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-20,000	Closed	-$70K	–	82
2014 Q3	$70K	Hold	20,000	–	–	0.04%	69
2014 Q2	$62K	Buy	+20,000	New	+$271K	0.03%	60

Other funds holding TVTX

Jennison Associates

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Amici Capital New York $257M AUM 4.88% 1-Year Est. Return

DSC Advisors's TVTX Position: Q4 2014 in Review

DSC Advisors sold out of Travere Therapeutics (TVTX) in Q4 2014, closing a stake of 20,000 shares — an estimated $180K sold.

DSC Advisors first reported a position in TVTX in Q2 2014 and held it in 2 quarters. The position peaked at $180K in Q3 2014. 65 funds tracked by Wall St. Rank hold TVTX as of Q4 2014.

DSC Advisors reported no remaining Travere Therapeutics position as of Q4 2014 after selling out during the quarter.
DSC Advisors sold 20,000 Travere Therapeutics shares in Q4 2014, an estimated $180K.
DSC Advisors first reported a position in Travere Therapeutics in Q2 2014 and held it in 2 quarters.
DSC Advisors's Travere Therapeutics position peaked at $180K in Q3 2014.
65 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2014.

Based on DSC Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.